Tags

Type your tag names separated by a space and hit enter

[Fast-dissolving sublingual tablets of piroxicam versus naproxen in the treatment of recurrent acute osteoarthrosis. Multicenter clinical trial].
Minerva Med. 1994 Mar; 85(3):89-96.MM

Abstract

An open comparative study was carried out to evaluate the efficacy and safety of piroxicam FDDF, for sublingual administration, versus naproxen in the treatment of osteoarthritis. Sixty-one patients with acute-phase osteoarthritis involving various joints are reported. They were treated with 20 mg/day piroxicam FDDF or with 1000 mg/day naproxen for a total of 4 weeks. Drug efficacy was evaluated on the base of the variation of spontaneous pain, pain on motion, functional limitation and capacity to perform a specific activity. The intensity of spontaneous pain on the first day showed a statistically significant improvement with both drugs, but the onset of analgesia was only after 15 minutes with piroxicam and after 1 hour with naproxen. The improvement in pain intensity increased on the first day and until the 7th day with both drugs, but the comparative analysis between the analgesic efficacy of the two treatments proved to be favourable to piroxicam. On the 7th day, pain on motion and the capacity to perform a specific activity showed a statistically significant improvement with both drugs, but the comparative analysis between the two treatments proved to be favourable to piroxicam. The two drugs showed the same efficacy in functional restriction. The local and systemic tolerability of piroxicam was good. Only 5 patients experienced 6 systemic side-effects, and 1 patients showed local side-effects, but 11 patients of the naproxen group showed 12 systemic side-effects. Thus piroxicam showed a better analgesic and anti-inflammatory efficacy than naproxen. Piroxicam proved to have a better systemic tolerability than naproxen. The local tolerability of piroxicam FDDF was good.

Authors+Show Affiliations

Cattedra e Scuola di Specializzazione in Reumatologia, Università degli Studi di Chieti.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Comparative Study
English Abstract
Journal Article
Multicenter Study
Randomized Controlled Trial

Language

ita

PubMed ID

8196849

Citation

Consoli, G, et al. "[Fast-dissolving Sublingual Tablets of Piroxicam Versus Naproxen in the Treatment of Recurrent Acute Osteoarthrosis. Multicenter Clinical Trial]." Minerva Medica, vol. 85, no. 3, 1994, pp. 89-96.
Consoli G, Covelli M, Di Matteo L, et al. [Fast-dissolving sublingual tablets of piroxicam versus naproxen in the treatment of recurrent acute osteoarthrosis. Multicenter clinical trial]. Minerva Med. 1994;85(3):89-96.
Consoli, G., Covelli, M., Di Matteo, L., Marcolongo, R., Tirri, G., La Montagna, G., & Pipitone, V. (1994). [Fast-dissolving sublingual tablets of piroxicam versus naproxen in the treatment of recurrent acute osteoarthrosis. Multicenter clinical trial]. Minerva Medica, 85(3), 89-96.
Consoli G, et al. [Fast-dissolving Sublingual Tablets of Piroxicam Versus Naproxen in the Treatment of Recurrent Acute Osteoarthrosis. Multicenter Clinical Trial]. Minerva Med. 1994;85(3):89-96. PubMed PMID: 8196849.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - [Fast-dissolving sublingual tablets of piroxicam versus naproxen in the treatment of recurrent acute osteoarthrosis. Multicenter clinical trial]. AU - Consoli,G, AU - Covelli,M, AU - Di Matteo,L, AU - Marcolongo,R, AU - Tirri,G, AU - La Montagna,G, AU - Pipitone,V, PY - 1994/3/1/pubmed PY - 1994/3/1/medline PY - 1994/3/1/entrez SP - 89 EP - 96 JF - Minerva medica JO - Minerva Med VL - 85 IS - 3 N2 - An open comparative study was carried out to evaluate the efficacy and safety of piroxicam FDDF, for sublingual administration, versus naproxen in the treatment of osteoarthritis. Sixty-one patients with acute-phase osteoarthritis involving various joints are reported. They were treated with 20 mg/day piroxicam FDDF or with 1000 mg/day naproxen for a total of 4 weeks. Drug efficacy was evaluated on the base of the variation of spontaneous pain, pain on motion, functional limitation and capacity to perform a specific activity. The intensity of spontaneous pain on the first day showed a statistically significant improvement with both drugs, but the onset of analgesia was only after 15 minutes with piroxicam and after 1 hour with naproxen. The improvement in pain intensity increased on the first day and until the 7th day with both drugs, but the comparative analysis between the analgesic efficacy of the two treatments proved to be favourable to piroxicam. On the 7th day, pain on motion and the capacity to perform a specific activity showed a statistically significant improvement with both drugs, but the comparative analysis between the two treatments proved to be favourable to piroxicam. The two drugs showed the same efficacy in functional restriction. The local and systemic tolerability of piroxicam was good. Only 5 patients experienced 6 systemic side-effects, and 1 patients showed local side-effects, but 11 patients of the naproxen group showed 12 systemic side-effects. Thus piroxicam showed a better analgesic and anti-inflammatory efficacy than naproxen. Piroxicam proved to have a better systemic tolerability than naproxen. The local tolerability of piroxicam FDDF was good. SN - 0026-4806 UR - https://www.unboundmedicine.com/medline/citation/8196849/[Fast_dissolving_sublingual_tablets_of_piroxicam_versus_naproxen_in_the_treatment_of_recurrent_acute_osteoarthrosis__Multicenter_clinical_trial]_ L2 - https://medlineplus.gov/osteoarthritis.html DB - PRIME DP - Unbound Medicine ER -